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Summary There is a pressing need to reduce the time and cost of developing new cytotoxic agents and to accurately identify clinically active
agents at an early stage. In this study, the differential staining cytotoxicity (DiSC) assay was used to assess the efficacy of the novel anti-
tumour cAMP analogue, 8-chloro-cAMP (8-Cl-cAMP) (and its metabolite 8-CI-adenosine) against 107 fresh specimens of human neoplastic
and normal cells. Diagnoses included chronic and acute leukaemias, myeloma, non-Hodgkin's lymphoma (NHL) and miscellaneous solid
tumours. The aim was to identify targets for subsequent phase 1, II and IlIl trials. 8-Cl-cAMP was tested at 4-985 gM, along with standard
chemotherapeutic drugs. 8-Cl-cAMP and its metabolite caused no morphologically observable cell differentiation but induced dose-
dependent cytotoxicity. Compared with untreated patients, previously treated chronic lymphocytic leukaemia (CLL) patients showed no
increase in ex vivo resistance to 8-Cl-cAMP (P = 0.878); minimal cross-resistance with other cytotoxic drugs was detected. Compared with
normal cells (mean LC9 = 1803gM), 8-Cl-cAMP showed significant ex vivo activity against CLL (117.0gM; P < 0.0001) and NHL (140.0 gM;
P < 0.0001), of which eight were mantle cell NHL (84.7 gIM), and greatest activity against cells from patients with acute myeloid leukaemia
(AML; mean LC 9 = 24.3 gm; in vitro therapeutic index 74-fold, P < 0.0001). Solid tumour specimens were comparatively resistant to
8-CI-cAMP. The results highlight the clinical potential of 8-Cl-cAMP, point to several new phase 1, II and IlIl trial possibilities and provide a
rationale for the inclusion of ex vivo cytotoxic drug evaluation in the drug development process.
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Drug development is a lengthy and expensive process, costing in
excess of£100 million per licensed drug. A crucial decision point
in the development of any new compound is whether to take it to
clinical trial, a process requiring substantial investment. Usually,
indications for a new cytotoxic compound are gleaned from cell
line and xenograft studies; toxicology tests are then undertaken
before the drug is entered into clinical trials (Carmichael, 1994).
The incorporation of a parallel series of ex vivo tests in different
neoplasms at an early juncture ('ex vivo' is used to denote the
determination of patient cellular response to drugs outside the
body as a surrogate for treating the patient), using methodologies
that predict well for subsequent patient response to known cyto-
toxic (Bosanquet, 1994), could increase the likelihood that drugs
progressed to trials will be clinically active.
Various ex vivo methods have been used to test new compounds
(Nagoumey et al, 1993; Larsson et al, 1994; Martin et al, 1994;
Hanauske et al, 1995). In this paper we outline a development of
this approach to drug evaluation whereby new agents are tested
against both fresh human neoplastic cells (from haematological
and solid tumours) and fresh human normal cells to identify
promising targets for subsequent phase I, II and Ill trials. The
experiments evaluate ex vivo cytotoxicity and the effect ofpatient
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pretreatment on theseresults, cross-resistance with othercytotoxic
agents, ex vivo plus in vitro therapeutic indices and ex vivo phase
II trials. Using 8-chloro-cAMP (8-Cl-cAMP), we have performed
ex vivo evaluation concurrently with clinical phase I trials.
8-Cl-cAMP is a cyclic adenosine 3',5'-monophosphate (cAMP)
analogue with novel properties, one of which is to down-regulate
the Rla and up-regulate the RII subunits of cAMP-dependent
protein kinase (Cho-Chung and Clair, 1993). RI is commonly
overexpressed in malignancy (North et al, 1994) and RH is under-
expressed; 8-Cl-cAMP can restore the normal balance of these
proteins in vitro (Pinto et al, 1992; Lange-Carter et al, 1993;
Rohlffet al, 1993a).
In addition to its regulatory effects, 8-Cl-cAMP is cytotoxic to
many cell types but, as has been suggested, only in the presence of
phosphodiesterases (for instance, in fresh but not heat-inactivated
serum; Borsellino et al, 1994), which activate the drug to the
metabolite 8-chloro-adenosine (8-Cl-adenosine) (Van-Lookeren-
Campagne et al, 1991; Taylor et al, 1992; Lange-Carter et al,
1993). 8-Cl-adenosine is a cytotoxic species (Langeveld et al,
1992a) but, although it is not a direct inhibitor of cAMP-depen-
dent protein kinases (Langeveld et al, 1992a), it down-regulates
RI and increases the R2/R1 subunit ratio.
8-Cl-cAMP has also been found to reverse doxorubicin resis-
tance in HL-60 cells that exhibit the multidrug-resistant (MDR)
phenotype but do not express the mdr-I gene product P-glycopro-
tein (Rholffet al, 1993b). However 8-Cl-cAMP does not affect the
doxorubicin sensitivity of MDR-expressing cell lines (Borsellino
et al, 1994), although it is able to down-regulate the expression of
MDR (Glazer and Rohlff, 1994; Scala et al, 1995).
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Thus, 8-Cl-cAMP has a unique spectrum of anti-cancer proper-
ties, which are currently being investigated in phase I trials
(Saunders et al, 1995; Tortora et al, 1995). We undertook our ex
vivo evaluation (using DiSC assay) concurrently with these trials
to identify phase II disease targets and drug combinations (8-Cl-
cAMP plus other cytotoxics) that would make good candidates for
phase III trials.
The DiSC assay is one of a number of ex vivo drug response
assays (Fruehauf and Bosanquet, 1993), but it is the assay of
choice forthis type ofdrug evaluation because ofits unique ability
to selectively identify tumour cell drug response within a hetero-
geneous cell culture. Published correlations for the DiSC assay
give an overall predictive accuracy of 83%, with a sensitivity of
94% and a specificity of 71% (Fruehauf and Bosanquet, 1993;
Bosanquet, 1994). The drug response information from test results
canprovide useful guidance inplanning patient treatment (Tidefelt
et al, 1989; Gazdar et al, 1990; Bosanquet, 1991; Weisenthal,
1991; Weisenthal and Kern, 1991; Fruehaufand Bosanquet, 1993;
Bosanquet, 1994; Bosanquet et al, 1995).
This analysis and presentation of results represents a compre-
hensive overview ofthe action of8-Cl-cAMP against fresh human
tumour cells ex vivo. In particular, the analysis with 8-Cl-cAMP
provides a number ofclear pointers for its future clinical develop-
ment. However, the general methodology is readily applicable to
other new cytotoxic drugs and could result in time-saving and
financial benefits by bridging the gap between preclinical and
clinical studies.
MATERIALS AND METHODS
DiSC assay
Specimen collection, tumour cell isolation and DiSC assay
methodology were all performed using published methods
(Bosanquet and Forskitt, 1989; Bosanquet, 1991; Bosanquet and
Bell, 1996a). Experiments were performed either in RPMI 1640
(Gibco) with 10% fresh (not heat-inactivated) fetal calf serum
(Gibco, Paisley, UK) or in serum-free medium (Ultraculture,
BioWhittaker, Wokingham, UK).
Briefly, 100gl ofcells at 8 x 105 ml-1 were incubated with drugs
in 0.6-ml polypropylene tubes for 4 days in duplicate. A mixture
offast green and nigrosin dyes and fixed duck erythrocytes (as an
internal standard) was added to the cell suspensions, followed by
cytocentrifugation of cells onto microscope slides and counter-
staining ofthe cells with a Romanowsky stain. LC90 values, i.e. the
lowest 8-Cl-cAMP concentrations at which 90% ofcells are killed
relative to controls, were determined in drug-treated samples by
LC90 evaluation (Bosanquet and Bell, 1996a).
Preparations ofmononuclear cells from blood and bone marrow
and cells isolated from other sources sometimes contained normal
cells. In these cases, normal and tumour cells were cultured
together. Resulting slides were counted twice: once to obtain a
tumour cell LC90, the second time to obtain a normal cell LC90
These results were used to determine the ex vivo therapeutic index
as described below.
Drugs
8-Cl-cAMP (8-chloro-cyclic adenosine 3',5'-monophosphate,
sodium salt; NSC 614491) was obtainedalready dissolved in 0.9 M
sodium chloride at 3.8 mg ml-' (9.85 mM) as the i.v. infusion (Toa
Table 1 Details of patients whose tumour cells were tested with 8-Cl-cAMP
and/or 8-CI-adenosine
Diagnosis No. previously Age Sex
treated/total (median) (M/F)
Acute undifferentiated leukaemia (AL) 1/1 1:0
Acute lymphoblastic leukaemia (ALL) 1/1 0:1
T-cell ALL (T-ALL) 1/1 20.8 0:1
Acute myeloid leukaemia (AML) 9/14 51.6 9:5
Acute biphenotypic leukaemia (mAL) 0/1 7.6 1:0
Chronic lymphocytic leukaemia (CLL) 21/48 63.5 36:12
Chronic myeloid leukaemia (CML) 0/1 66.0 0:1
Hairy cell leukaemia (HCL) 1/1 74.4 1:0
Myeloma (Mye) 2/2 58.5 1:1
Non-Hodgkin's lymphoma (NHL) 12/14 57.1 13:1
Plasma cell leukaemia (PCL) 0/1 14.4 1:0
T-cell prolymphocytic leukaemia (T-PLL) 1/1 56.2 0:1
Breast 1/2 44.9 0:2
Head and neck 0/2 59.1 2:0
Kidney 0/1 53.2 1:0
Small-cell lung cancer (SCLC) 1/1 43.1 1:0
Mesothelioma 0/1 64.0 0:1
Ovary 2/3 41.8 0:3
Prostate 0/1 67.3 1:0
Total no. of tumours 53/97 68:29
aAdult leukaemias
Nenryo Kogyo, Saitama-Ken, Japan); it is chemically stable in this
vehicle (Cummings et al, 1994). 8-Cl-adenosine was purchased
from Biolog Life Science Institute (Bremen, Germany) and
dissolved in water for injections BP at an equimolar concentration
(2.973 mg ml-1). Both drugs were serially diluted (five fourfold
concentration steps) with phosphate-buffered saline (PBS) and
stored at -70°C until required. At time of assay, the drugs were
thawed and diluted lOx into the test system to provide final
concentrations of985, 246, 61.6, 15.4 and 3.85 gM.
Results in Figure 2 confirm the cytotoxic equivalence of 8-Cl-
cAMP in serum-containing medium and 8-Cl-adenosine in serum-
free medium. Thus ex vivo results subsequently presented as
8-Cl-cAMP in the text and in Figures 3, 4 and 6 include some
results from 8-Cl-adenosine in serum-free medium (7 out of48 in
Figures 3 and 4; 23 out of 115 including 3 out of 18 normals in
Figure 6).
Data analysis
All LC9 values were logarithmically transformed before the mean
and s.d. values were calculated giving, unless otherwise stated,
geometric mean x. geometric s.d. (Bosanquet and Bell, 1996b).
Specimens from eight patients yielded paired tumour and normal
cell LC9 values; from each of these, an ex vivo therapeutic index
could be calculated:
Patient ex vivo therapeutic index = normal cell LC90
tumour cell LC90
A general therapeutic index could also be calculated using the
mean ofall normal cell results. This is graphed on the right handy-
axis ofFigure 6 and is defined thus:
In vitro therapeutic index =mean of all normal cellLC9 values
tumour cell LC9
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Figure 1 Effect of serum on the dose-response of 8-Cl-cAMP against CLL
lymphocytes. Results are arithmetic means ± 1.96 s.e.m. of 31 experiments
in serum-containing and 38 experiments in serum-free medium
Pearson correlation coefficients (r) were calculated on the log-
transformed LC9 values with pairwise missing-value treatment.
Significance was calculated using Student's two-tailed t-test with
Bonferroni correction.
Ex vivo cytotoxic drug evaluation
A synthesis of ex vivo experiments and data analysis provides a
thorough overview of the drug's action against fresh human
tumour cells. These experimental components include:
1. ex vivo cytotoxicity ofthe drug;
2. effect ofpatient pretreatment on ex vivo cytotoxicity;
3. cross-resistance ofthe new drug with known cytotoxic agents;
4. ex vivo phase II trials in various diagnoses;
5. cytotoxicity against normal human cells;
6. ex vivo (intra-patient) therapeutic index;
7. in vitro therapeutic index;
8. other drug-specific ex vivo experiments - for instance
investigation ofex vivo differentiation with 8-Cl-cAMP.
RESULTS
Specimens
One hundred and seven specimens from a variety of tumour types
tested with 8-Cl-cAMP and/or 8-Cl-adenosine yielded tumour
LC9 values; eight of these yielded both normal and tumour LC90
values and 10 specimens yielded only normal cell LC9 results.
Thus, the results reported here are from 97 tumour specimens
(Table 1) and 18 normal specimens (Table 2). A further series of
27 specimens ofCLL were also tested with 8-Cl-cAMP in serum-
free medium, yielding data for Figures 1 and 2; but as the drug is
less active under these conditions, these results were excluded
from further analysis.
Table 2 Characteristics of normal cells that were tested with 8-Cl-cAMP
and/or 8-CI-adenosine
Patient diagnosis Specimen Predominant cell type(s)
source after 4 days in culture
AMLa Blood Lymphocytes + neutrophils
AMLa Marrow Neutrophil + lymphoid forms
AML Blood Lymphocytes + neutrophils
AMLa Marrow Neutrophil + lymphoid forms
AML Marrow Neutrophil + lymphoid forms
Myelomaa Marrow 95% Myeloid stages
NHLa Pleural fluid 90% Small lymphocytesb
Mantle cell NHLa Marrow 75% Neutrophils
Mantle cell NHLa Blood 80% Macrophages
T-PLLa Blood Neutrophils + macrophages
Breast Pleural fluid 90% Lymphocytes
Head and neck Lymph node 90% Lymphocytes
Melanoma Pleural fluid Macrophages + lymphocytes
Pancreas Ascites 90% Lymphocytes
Prostate Ascites 99% Macrophages
Unknown primary Ascites Lymphocytes + macrophages
Uterus Ascites 95% Macrophages
Benign Lymph node 99% Lymphocytes
aThese eight specimens contained both normal and tumour cells, counted
separately from the same slides. bThis patient's malignant cells were a
distinct population of large blasts.
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Figure 2 Cytotoxicity of 8-Cl-cAMP and 8-CI-adenosine against CLL
lymphocytes in (A) serum-free medium and (B) RPMI 1640 containing 10%
fetal bovine serum. Paired experiments are joined by lines. *, Mean xv s.d.
of group
Ex vivo induction of differentiation by 8-Cl-cAMP
Cells were carefully assessed after the 4-day incubation to ascer-
tain whether differentiation had been induced ex vivo in AML
specimens, in which it had been reported with other methodologies
(Pinto et al, 1992). Morphologically, we might have expected
smaller proportions of myeloid blasts at the end of incubation
and increased proportions of myelocytes and metamyelocytes.
However, no obvious differentiation was observed, even at the
lowest 8-Cl-cAMP concentration tested.
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cytotoxicity
The effect of patient treatment with cytotoxic drugs on 8-Cl-
cAMP LC90 values in CLL is presented in Figure 3. The results
show that treatment did not induce ex vivo resistance to
8-Cl-cAMP (P = 0.878). Similar results were found with other
leukaemic specimens ofvarious diagnoses, suggesting that lack of
inducedresistance to 8-Cl-cAMP is not disease specific (Figure 6).
Cross-resistance of 8-Cl-cAMP with other drugs
All specimens tested with 8-Cl-cAMP were also tested with other
cytotoxic drugs. Cross-resistance could be determined by plotting
8-Cl-cAMP LC9 values against drug LC9 values for all patients
with the same disease. With CLL specimens, but no other tumour
types, there was sufficient data (n > 25) to investigate 8-Cl-cAMP
cross-resistance with 10 drugs, and the results are shown in Figure
4. No drug showed marked cross-resistance with 8-Cl-cAMP. The
largest correlation coefficients were seen with the anthracyclines
doxorubicin (r = 0.525, P < 0.01) and epirubicin (r = 0.500,
P < 0.01). Of particular interest is the almost complete lack of
cross-resistance with pentostatin and with cladribine and fludara-
bine, two purine analogues that have similar structures (Figure 5)
and known clinical activity against CLL, AML and NHL. Other
tumour types may exhibit different cross-resistance profiles.
No prior
chemotherapy
Prior
chemotherapy
Figure 3 Effect of patient prior cytotoxic chemotherapy on subsequent ex
vivo 8-Cl-cAMP cytotoxicity in CLL. *, mean x-'- s.d. of group. Open symbols,
no prior chemotherapy; closed symbols, pror chemotherapy
Cytotoxicity of 8-Cl-cAMP and 8-CI-adenosine
8-Cl-cAMP elicited a dose-dependent cell kill between 4 and
985 pJm in almost all specimens tested. Only in single specimens of
breast, prostate, mesothelioma and head and neck tumours was
negligible cell kill observed, even at the highest concentrations
tested. Dose-response results of experiments with CLL lympho-
cytes in serum-containing and serum-free media are presented in
Figure 1. This shows an approximately 10-fold increase in the
drug concentration required to kill cells in the absence of serum,
confirming work by others (Van-Lookeren-Campagne et al, 1991;
Taylor et al, 1992; Lange-Carter et al, 1993) but suggesting that 8-
Cl-cAMP is cytotoxic in the absence ofphosphodiesterases, albeit
at higher concentrations.
In Figure 2, the difference between the cytotoxicity of 8-Cl-
cAMP and 8-Cl-adenosine to CLL is presented, both in serum and
in serum-free media. 8-Cl-adenosine is not significantly more
toxic than 8-Cl-cAMP in RPMI 1640 containing 10% fetal bovine
serum (meanLC, values 109.7 gM and 77.6 gM respectively, P =
0.484; six paired experiments, P = 0.205) and the correlation coef-
ficient (r) between 8-Cl-cAMP and 8-Cl-adenosine was 0.966
(n = 6 CLL specimens, P = 0.002). However the paired results in
serum-free medium gave a mean difference in LC9 of 35.9-fold
(mean LC9 values for 8-Cl-cAMP and 8-Cl-adenosine 3942 gM
and 110 ,UM respectively, P < 0.0001). Subsequent data include
results from 8-Cl-cAMP in serum and 8-Cl-adenosine in serum-
free medium.
Ex vivo phase 11 trials
In Figure 6, 8-Cl-cAMP LC90 values are plotted by tumour type
and are compared with the 18 specimens that yielded normal cell
results. The mean LC9 for the normal cells, 1803 ,UM, comprises
results from specimens ofblood, ascites, pleural fluid, lymph node
and bone marrow taken from cancer patients (Table 2).
Nine solid tumours were more resistant than the normal mean
LC90 value (see Figure 6 legend for diagnosis details), but 8-Cl-
cAMP showed greateractivity against one specimen each ofprevi-
ously treated small-cell lung cancer and de novo kidney cancer.
Further testing is clearly required to identify which solid tumours
would be potential targets for the drug.
Almost all leukaemic specimens were more sensitive ex vivo
than the normal cell meanLC90 value. Thus, mean LC9 values for
CLL and NHL were 117.0 ,UxM x. 3.29 (compared with normal
cells, P < 0.0001) and 140.0 gmM -X+ 3.98 (P < 0.0001) respectively,
and eight of ten miscellaneous leukaemias were also more sensi-
tive ex vivo than the normal cell mean value (Figure 6). Ofthe 14
NHLs, eight were mantle cell NHL by the REAL classification
(previously called centrocytic; Harris et al, 1994) and were
slightly (but not significantly) more sensitive to 8-Cl-cAMP (mean
LC9 = 84.7 gmM X. 2.64) than the other NHLs. The most striking
results were with AML: mean LC 9 = 24.3 ,UM X-e- 4.06 (compared
with normal cells, P < 0.0001). Three AML specimens were the
most sensitive specimens tested (Figure 6). These findings in
AML are particularly interesting as many ofthepatients hadprevi-
ously received cytotoxic chemotherapy (for details, see Figure 6
legend). The most resistant AML specimen was from a pretreated
patient with primary refractory disease (FAB-type Ml).
Patient ex vivo therapeutic index
The eight sets of paired normal and tumour cell data gave
ex vivo (intra-patient) therapeutic indices (TI) of 2.5-100 (mean
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Figure 4 Cross-resistance of 8-Cl-cAMP with other cytotoxic agents in CLL There was no significant cross-resistance (P> 0.05) with cladribine, fludarabine,
pentostatin, chlorambucil and mafosfamide (in vitro surrogate for cyclophosphamide in vivo); 0.05> P> 0.01 with methylprednisolone, prednisolone and
vincristine; and 0.01 > P> 0.001 with doxorubicin and epirubicin
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Geometric mean
normal cell LC0
Normal AML
cells
CLL NHL Other Solid
leukaemias tumours
Tumour type
Figure 6 Ex vivo phase 11 trials and in vitro therapeutic index of 8-CI-cAMP. * ± bar indicates mean x+ s.d. of group. The nine relatively resistant solid tumours
were: three ovarian, one breast and one head and neck (resistant); one prostate, one mesothelioma, one breast and one head and neck (very resistant).
Normal cell LCgo values are from AML (El), myeloma (c), mantle cell lymphoma (V), other NHL (A\), T-PLL (tv), benign lymph node (*) and solid tumours (-)
of breast, head and neck, melanoma, pancreas, prostate, uterus and unknown primary. PR-AML, primary refractory AML-M1. For abbreviations see Table 1.
Dotted lines link results from co-incubated normal (lymphoid cells and neutrophils) and tumour cells (myeloblasts) from three individual AML patients. Open
symbols, untreated; filled symbols, patient previously treated. Details of previous chemotherapy administered to these patients are as follows: seven AML
patients were previously treated with cytarabine-containing regimens (primarily ADE or DAT) and five of these had also received idarubicin, amsacrine or both;
one AML patient was initially diagnosed as NHL before immunocytochemical analysis and had received chlorambucil only; pretreatment details of a further AML
patient are unknown; 21 CLL patients had received a median of two chemotherapy regimens: chlorambucil (21/21), cyclophosphamide [chiefly
cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP); 9/21], anthracycline (doxorubicin, epirubicin or mitoxantrone; 11/21); antimetabolite
(chiefly fludarabine; 11/21); 12 NHL patients had received a median of two regimens: chlorambucil, CHOP or COP (no doxorubicin) (12/12), anthracycline
(chiefly doxorubicin; 10/12), fludarabine (5/12), ± other treatment (carboplatin, cisplatin, etoposide, bleomycin, high-dose dexamethasone, radiotherapy; 6/12).
The relatively sensitive ALL patient had received CHOP, methotrexate, vincristine, high-dose cytarabine, amsacrine, doxorubicin and fludarabine. The T-ALL
patient had been treated according to the UKALL XII trial. The T-PLL patient had received CAMPATH and prednisolone. The HCL patient had received
chlorambucil followed by CHOP. The mAL patient was heavily pretreated with three AML-based regimens and then ALL-based chemotherapy. The two myeloma
patients had received two and four drug regimens respectively. The relatively sensitive SCLC patient had received epirubicin plus ifosfamide followed by
cisplatin plus etoposide
TI = 10.2 x. 1.52; paired t-test, P = 0.0009). The three paired
AML LC9 values in Figure 4 had a mean TI of 15.4 (paired t-test,
P = 0.0073).
DISCUSSION
The cost ofbringing a new drug to the clinic is considerable. With
the relatively short time span of patent cover, during which the
financial outlay of drug development must be recouped, the time
taken to perform phase II trials must be kept to a minimum. The
results obtained using the methodology presented here have impli-
cations for the future clinical development of new anti-cancer
drugs. These experiments could be conducted concurrently with
toxicology testing or, as in this case, alongside a phase I clinical
trial, before scale-up of drug manufacture becomes necessary.
Alternatively, a series of potential candidate drugs could be
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investigated at an earlier stage to determine which would be most
relevant to take to the clinic, i.e. the most active against the target
tumour in vitro, least cross-resistant with known cytotoxics and with
the best ex vivo and in vitro therapeutic indices. In conjunction with
other methods of screening for new cytotoxic agents (Weisenthal,
1992; Carmichael, 1994; Boyd and Paull, 1995), this methodology
could aid decision-making in cytotoxic drug development.
The results presented here are somewhat different from those
generated using the colony-forming (Martin et al, 1994; Hanauske
et al, 1995) and fluorometric microculture cytotoxicity (FMC)
assays (Larsson et al, 1994) to screen for new anti-cancer agents;
we have measured one-log cell kill (as opposed to 50% or 0.3 log)
(Nagourney et al, 1993; Larsson et al, 1994; Martin et al, 1994;
Hanauske et al, 1995) on all morphologically identifiable tumour
cells [rather than .0.004% ofcells that form colonies (Martin et al,
1994; Hanauske et al, 1995)]. We have also determined the cyto-
toxic effect on normal and leukaemic as well as solid tumour cells,
in a 4-day test (rather than 14-28 days). As such, we consider the
strategy presented here provides a significant step forward in the
development of ex vivo cytotoxic drug evaluation.
These results with 8-Cl-cAMP have highlighted this drug's
potential as an effective anti-cancer drug in a number of ways. 8-
Cl-cAMP has recently undergone two phase I trials using contin-
uous, low-dose infusion (Saunders et al, 1995; Tortora et al, 1995)
with the aim of inducing terminal differentiation of tumour cells
through the up-regulation ofthe RII-regulatory subunit ofcAMP-
dependent protein kinase (Cho-Chung and Clair, 1993). The data
presented here suggest cytotoxicity, not differentiation, as the
mode of action in our system, even at the lowest concentration
tested (3.85 gM). A similar lack of differentiation was observed
with glioma cell lines (Langerveld et al, 1992b). Thus, the ex vivo
mode oftumour cell kill by 8-Cl-cAMP is probably similar to that
of other cytotoxic agents, suggesting that i.v. bolus administration,
with the aim of inducing cytotoxicity rather than differentiation,
should be investigated.
In this work, we have required higher concentrations ex vivo than
plasma concentrations measured after continuous i.v. infusion in
phase I trials. Two factors may account for this. Firstly, the rationale
for the dose intensities and regimens of 8-Cl-cAMP in these phase I
trials has been based on its capacity as a modulator of cAMP
-dependent protein kinases. Low-dose continuous i.v. infusion
(10 days ofinfusion every 3 weeks at 0.2 or 0.25 gg kg-' h-1; Tortora
et al, 1995) has therefore been one chosen mode of administration,
and this has yielded plasma concentrations of approximately
2-5 gM. Again, as we have measured cytotoxicity rather than diffe-
rentiation, higher ex vivo concentrations are to be expected. Areas
under the time x concentration curve may well be similar.
Secondly, we expect mean ex vivo LC90 concentrations in
general to be of a similar order to i.v. bolus injection peak plasma
concentrations (Fruehauf and Bosanquet, 1993). Peak plasma
concentrations by this administration are typically 30- to 100-fold
greater than those obtained for the same drug by continuous
infusion. (For instance, for carboplatin compare Allsopp and
Sewell, 1995 with Harland et al, 1984 and Reece et al, 1987) Thus,
there is no obvious discrepancy between the LC90 values presented
in this work and drug levels measured in vivo.
An excellent ex vivo therapeutic index was found in CLL, NHL
and particularly AML, suggesting that they are strong candidates for
early phase II trials of 8-Cl-cAMP. The identification of sensitivity
in mantle cell NHL is of special interest as this is a particularly
resistant disease (Vandenberghe, 1994).
The moderate cross-resistance between 8-Cl-cAMP and
doxorubicin sensitivity is unexpected, but it confirms a report
using cell lines that demonstrated hypersensitivity both to
topoisomerase II inhibitors and 8-Cl-cAMP (North et al, 1994),
suggesting some interaction between the two cytotoxic pathways.
The relative lack of cross-resistance with other cytotoxic drugs
(Figure 4) gives indications for phase III combinations worthy of
consideration, in particular with the alkylating agents (including
cisplatin; Nishio et al, 1992) and vinca alkaloids. Even the
antimetabolites with very similar structures, i.e. fludarabine,
cladribine (Figure 5) and pentostatin, are essentially non-cross-
resistant with 8-Cl-cAMP (Figure 4). The role of 8-Cl-cAMP in
overcoming multiple drug resistance by down-regulating mdr-1
expression (Yokozaki et al, 1993; Glazer and Rohlff, 1994; Scala
et al, 1995) provides a rationale for its use in combination with
drugs such as the anthracyclines. Further work, exploring 8-Cl-
cAMP in combination with other drugs and cross-resistance in
other tumour types could be usefully undertaken ex vivo.
Prior administration of various chemotherapeutic agents
induced no discernible ex vivo resistance to 8-Cl-cAMP (Figure 3,
also Figure 6) in contrast to many other drugs tested in these and
other CLL specimens. For instance, highly significant increases in
treatment-induced resistance were seen with other antimetabolites
ex vivo, including cytarabine, fludarabine, cladribine and pento-
statin (Bosanquet and Bell, 1996b). This suggests that 8-Cl-
cAMP's mode of action is unique among cytotoxic drugs despite
the similarity of structure (Figure 5). Work with paired cell lines
(sensitive/resistant to doxorubicin or radiation) supports this
proposition, with no difference in 8-Cl-cAMP cytotoxicity
between resistant and wild-type cell lines observed (Borsellino et
al, 1994; Buraczewska et al, 1994). After development of clinical
drug resistance to initial therapy, a patient's tumour might still be
sensitive to 8-Cl-cAMP, especially ifthe drug is shown to be active
ex vivo. Indeed, some patients are still very sensitive to 8-Cl-
cAMP even after multiple chemotherapy (Figure 6).
In conclusion, the general methodology of ex vivo cytotoxic
drug evaluation, undertaken concurrently with phase I trials in
vivo, could enable targets for phase II trials to be identified more
rapidly. This should reduce the time and cost of licensing a new
cytotoxic drug and thereby benefit both pharmaceutical companies
and patients.
For 8-Cl-cAMP in particular, the lack of induction ofresistance
by previous cytotoxic therapy, the lack ofmarked cross-resistance,
the good ex vivo therapeutic index and novel mode of action all
combine to suggest that 8-Cl-cAMP is an exciting new cytotoxic
agent that could have a considerable role in the future treatment of
neoplastic disease. The results suggest: a new phase I trial with a
schedule that will induce cytotoxicity as well as inhibition; phase
II trials in CLL, (mantle cell) NHL and particularly AML; and
combinations of 8-Cl-cAMP with other cytotoxic agents for both
ex vivo and clinical phase III investigation.
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